Fundraising Fox

Jason Rhodes

Investor

Partner at Atlas Venture · Board director at Dyne Therapeutics · Board director at Generation Bio

Cambridge, Massachusetts, United States

Writes $500K – $5M checks · typically $2M

About

Jason Rhodes is a partner at Atlas Venture focused on creating and building therapeutics companies. He was the founding CEO of Dyne Therapeutics and Rectify Pharmaceuticals and founding CEO of Disarm Therapeutics (acquired by Eli Lilly), and previously held leadership roles at Alnylam Pharmaceuticals and Epizyme. Earlier he was a founder and partner at Fidelity Biosciences (now F-Prime Capital), where he led therapeutics investments. He holds a BA from Yale University and an MBA from the Wharton School.

Contact· self-published, not guessed

Invests in

Biotech

Board director at Dyne Therapeutics

Intro paths

→

In turn, Jason can intro founders to Dyne Therapeutics's investors below.

Dyne Therapeutics's investors · 5

Atlas VentureCambridge · $500K – $1M checks · since 2020ForbionNaarden · since 2020Hercules Capital, Inc.San Mateo · $5M – $500M checks · since 2026MPM BioImpactBoston · $1M – $15M checks · since 2020Vida VenturesLos Angeles · since 2020

Co-founders at Dyne Therapeutics

RS
Romesh Subramanian, Ph.D.Executive Officer

Board director at Generation Bio

Intro paths

→

In turn, Jason can intro founders to Generation Bio's investors below.

Generation Bio's investors · 4

Atlas VentureCambridge · $500K – $1M checksF-Prime CapitalCambridge · $3M – $10M checks · since 2018Foresite CapitalWest HollywoodInvusNew York

Experience

  1. American Academy in RomeTrusteecurrent2026 — present
  2. Atlas VenturePartnercurrent2014 — presentCambridge, MA
  3. Rectify PharmaExecutive Chair (and founding CEO)current2020 — present
  4. Dyne TherapeuticsChairman (and founding CEO)current2017 — presentCambridge, MA
  5. Berklee College of MusicPresidential Advisory Council, Member2009 — 2022
  6. Disarm Therapeutics (acquired by Lilly in 2020)Chairman (and founding CEO)2016 — 2020
  7. EpizymePresident and CFO2010 — 2014NASDAQ: EPZM www.epizyme.com
  8. AlnylamVice President, Business Development2007 — 2010
  9. Fidelity Biosciences(F-Prime)Partner2001 — 2007

Skills & more

Strategy69Leadership9Management6Strategic Planning6Venture Capital82Corporate Development33Alliances2Investments13Life Sciences32Biotechnology65Strategic Partnerships63Business Alliances6
+12 moreOncologyMergersPrivate EquityDrug DiscoveryLifesciencesTechnology TransferPharmaceutical IndustryCommercializationBusiness DevelopmentStrategic AlliancesProduct DevelopmentProduct Management

From Jason's professional profile.

Investments

Led

FoldRx

Board seats

AAVantgarde BioAccent TherapeuticsDisarm TherapeuticsDyne TherapeuticsK36 TherapeuticsKaryoVerseMithrilRectify PharmaceuticalsWeaver

Per the firm's website.

Colleagues at Atlas Venture

Aimee Raleigh
Principal at Atlas Venture
Bruce Booth
Partner at Atlas Venture
Chelsea Johnson
Principal at Atlas Venture
David Grayzel
Partner at Atlas Venture
Jean-François Formela
Partner at Atlas Venture
Jernej Godec
Principal at Atlas Venture
Jodie Morrison
Venture Partner at Atlas Venture
Josh Powers
Associate at Atlas Venture

Network4

Aimee Raleigh
Principal at Atlas Venture
Bruce Booth
Partner at Atlas Venture
Chelsea Johnson
Principal at Atlas Venture
David Grayzel
Partner at Atlas Venture

Investors connected to Jason in public investor directories — a warm-intro map.

Frequently asked questions

Who is Jason Rhodes?
Jason Rhodes is a partner at Atlas Venture focused on creating and building therapeutics companies. He was the founding CEO of Dyne Therapeutics and Rectify Pharmaceuticals and founding CEO of Disarm Therapeutics (acquired by Eli Lilly), and previously held leadership roles at Alnylam Pharmaceuticals and Epizyme. Earlier he was a founder and partner at Fidelity Biosciences (now F-Prime Capital), where he led therapeutics investments. He holds a BA from Yale University and an MBA from the Wharton School.
Where does Jason Rhodes work?
Jason Rhodes is Partner at Atlas Venture and Board director at Dyne Therapeutics and Board director at Generation Bio.
What does Jason Rhodes invest in?
Jason Rhodes invests in Biotech.
What check size does Jason Rhodes write?
Jason Rhodes typically writes checks of $500K – $5M.
What boards does Jason Rhodes sit on?
Jason Rhodes holds tracked board seats at AAVantgarde Bio, Accent Therapeutics, Disarm Therapeutics, Dyne Therapeutics, K36 Therapeutics, KaryoVerse, Mithril, Rectify Pharmaceuticals, Weaver.
What companies has Jason Rhodes invested in?
Investments tracked here include FoldRx.
Where did Jason Rhodes go to school?
Jason Rhodes studied at Yale University (BA, History - modern diplomatic and financial history); The Wharton School (MBA).
Does Jason Rhodes lead rounds?
Yes — Jason Rhodes has led 1 tracked investment.

Founder mafias

The Wharton School mafia209

Also came through, then founded or led a company.

Kunal BahlMarketing and Operations StrategyFounded SnapdealJack AbrahamBachelors of Science in Economics *Dropped outFounded Sauron +8Ankur JainBachelor of Science (BS)Founded Kairos +3Christian SchadeMaster of Business Administration - MBAFounded Halda Therapeutics +2Eric HeilMBAFounded Ladderbio +1Daniel FetnerMaster of Business Administration (MBA)Founded Instrument Capital +1

+ 202 more

Yale University mafia190

Also came through, then founded or led a company.

Michael SeibelBAFounded SocialCamBen SilbermannB.A.Founded Audiobeta +2Justin KanPhysics and PhilosophyFounded Stash +6Kevin RyanBAFounded Business Insider +2Harry GrunerFounded Hilos +2Emmett ShearBSFounded Softmax +2

+ 183 more

Atlas Venture mafia13

Also came through, then founded or led a company.

Nessan BerminghamAnalyst - Associate - Principle - PartnerFounded Korro Bio +2Romesh SubramanianEntrepreneur In ResidenceFounded RaNA Therapeutics +2Phillip SamayoaVenture PartnerFounded Generation Bio +2Sumit AgarwalAssociateFounded Shape Security +1Kevin BittermanPartnerFounded Editas MedicineJohn MaraganoreVenture PartnerFounded Alnylam

+ 6 more

Dyne Therapeutics mafia4

Also came through, then founded or led a company.

Romesh SubramanianCSO/FounderFounded RaNA Therapeutics +1Phillip SamayoaCo-FounderFounded Generation Bio +1Sudhir AgrawalMember, Scientific Advisory BoardFounded Aldebaran Therapeutics

Generation Bio mafia3

Also came through, then founded or led a company.

Phillip SamayoaSenior Vice President, Head of Corporate DevelopmentFounded Dyne Therapeutics +1Jeffrey M. JonasDirectorFounded Sage Therapeutics

Same school

Also attended Yale University651

Ann Miura-KoCo-founding Partner at FloodgateDavid SzeAdvisory Partner at GreylockMichael SeibelPartner Emeritus at Y CombinatorBen SilbermannCo-founder of PinterestZheela QaiserInvestor at Index VenturesAnthony PhilippakisInvestor at GV (Google Ventures)

+ 645 more

Also attended The Wharton School1,557

Fred WilsonCo-founder & Partner at Union Square VenturesSarah GuoFounder & General Partner of ConvictionJosh KopelmanFounder and Partner at First Round CapitalAydin SenkutFounder & Managing Partner at FelicisKunal BahlCo-founder of Snapdeal; co-founder of Titan CapitalJack AbrahamFounder, CEO & Managing Partner of Atomic

+ 1,551 more

Shared employers

Also worked at American Academy in Rome1

Tiffany ChuCEO & Cofounder at Remix

Also worked at Rectify Pharma4

David SteinbergGeneral Partner at Longwood FundAnnie MitsakPartner at Cure VenturesMarco BoorsmaGeneral Partner at ForbionJodie MorrisonVenture Partner at Atlas Venture

Also worked at Dyne Therapeutics5

Sudhir AgrawalInvestor at 82VSRomesh SubramanianVenture Partner at Scion Life SciencesDoug KerrScience Advisor at Exceptional VenturesPhillip SamayoaPrincipal at Atlas VentureStephen CurtisManaging Partner at MPM BioImpact

Also worked at Berklee College of Music6

Steve HoltzmanBio Advisor at Amplify PartnersMichael A. BrownPartner at Shield CapitalGavin BergerBoard of Directors at Vermont Center for Emerging Technologies (VCET)Matt ManninoSenior Manager, Marketing Operations at Acme InnovationDan ServantesSenior Director, Marketing and Strategy at Acme InnovationPaul CirielloInvestor at Fairhaven Capital Partners